Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake

Executive Summary

The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.

You may also be interested in...



Janssen Secures Only Partial Win In Appeal Against English Funding Snub For Spravato

Of the nine specific appeal points raised against NICE’s rejection of the company’s antidepressant nasal spray, Spravato, just one was upheld.

New ‘Emergency’ Market Beckons For Spravato Depression Spray

The therapeutic indication of Spravato is set to be expanded in the EU after receiving the thumbs up from the European Medicines Agency. The nasal spray has been shown to reduce depressive symptoms in just four hours and would fill a key unmet need, says the drug’s developer, Janssen.

EU Approval Delay for Janssen’s Spravato?

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel